小分子药物治疗炎症性肠病的最新研究进展

Recent advances in small molecule drugs for inflammatory bowel disease

炎症性肠病(IBD)是一种慢性非特异性肠道炎性疾病。生物制剂具有临床疗效好, 但是部分患者可能因出现不良反应而停止治疗。新型口服小分子药物具有分子量小、更易通过细胞膜和半衰期短的特点, 对IBD具有良好的疗效。本文论述治疗IBD的小分子药物的研究进展, 以期指导临床应用。

Inflammatory bowel disease is a chronic non-specific intestinal inflammatory disease.Biological agents have good clinical efficacy,but some patients may stop treatment due to adverse reactions.New oral small molecule drugs have the characteristics of small molecular weight,easier passage through cell membrane and short half-life,and have good curative effect on IBD.This article reviews the research progress of small molecule drugs for the treatment of IBD,in order to guide clinical application.